India Pharma Outlook Team | Tuesday, 17 November 2026
Natco Pharma is looking beyond Revlimid to rebuild growth through three oncology drug opportunities.
The company plans to advance carfilzomib, trabectedin and olaparib as generic competition continues to erode sales of lenalidomide, its version of Bristol Myers Squibb's blockbuster cancer drug.
The shift comes as the drugmaker faces declining revenue and profitability.
Chief Executive Rajeev Nannapaneni outlined the three-drug pipeline during an analyst interaction, identifying the launches as potential growth drivers over the coming quarters.
Natco Pharma's revenue from operations fell 29 percent year-on-year to Rs 967 crore in Q2 FY27, compared with Rs 1,363 crore in the corresponding quarter last year. Net profit declined 61 percent to Rs 202 crore from Rs 517 crore.
Lower lenalidomide sales contributed to the decline as generic competition eroded the company's market lead. The financial performance highlights the need for Natco to develop new revenue streams beyond its established oncology business.
Also Read: Moving Indian Pharma from Volume to Value Through Innovation and Strategic Partnerships
Natco plans to launch generic carfilzomib in the US across 60 mg, 30 mg and 10 mg strengths. Six other players will compete in the 60 mg segment, while Natco ranks among the first-to-file applicants for one of the two lower strengths.
For trabectedin, a chemotherapy drug used for ovarian and soft-tissue cancers, Natco ranks among two first-to-file applicants with the US FDA. The company also plans to expand its olaparib business, involving a PARP inhibitor, into Canada and Brazil.
However, converting these opportunities into sales will depend on competition and commercial execution. Natco's semaglutide business also faces pricing pressure, with monthly sales of Rs 1.5–2 crore but no breakeven yet. CEO Nannapaneni does not expect a near-term turnaround in the segment.